Palo Alto-based Anacor (NASDAQ:ANAC) said its compound AN3661 will be developed to treat malaria.
AN3661 was developed as part of a research agreement signed by the two parties in April 2010 to identify new compounds for the treatment of malaria using Anacor’s boron chemistry.
No comments:
Post a Comment